Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

TenNor Therapeutics Raises $71M in Hong Kong IPO – Antimicrobial Pipeline Targets H. pylori and Implant-Associated Infections

Fineline Cube May 14, 2026
Company Deals Drug

Fosun Pharma Secures Global Rights to AriBio’s Alzheimer’s Drug AR1001 in $240M Deal – PDE-5 Inhibitor Shows Promise in Phase III

Fineline Cube May 14, 2026
Company Deals

Merck & Co. Forges Four Strategic Partnerships with Chinese Biotechs to Advance Autoimmune and Oncology Pipeline Through MCICC Platform

Fineline Cube May 14, 2026
Company Deals

Shanghai Immunocan Biotech Secures RMB 250M Series A Led by Vivo Capital to Advance Gene-Edited Antibody Discovery Platforms

Fineline Cube May 13, 2026
Company Deals

Shenzhen Weiguang Biological to Raise RMB 1.5B in Private Placement to Fund Smart Industrial Base Expansion

Fineline Cube May 13, 2026
Policy / Regulatory

China’s CDE Reports Record Drug Review Activity in 2025 – Breakthrough Therapy Designations Surge 11% as Regulatory Filings Hit 20,149

Fineline Cube May 14, 2026
Company Drug

Pfizer’s Hympavzi Gains European Approval for Hemophilia with Inhibitors – Novel TFPI-Targeting Therapy Offers Weekly Subcutaneous Alternative to Factor Replacement

Fineline Cube May 14, 2026
Company Drug

Henlius Biotech Secures Australian TGA Approval for HLX48 Phase I Trial – Novel EGFR/c-Met Bispecific ADC Targets Advanced Solid Tumors

Fineline Cube May 14, 2026
Company Deals

Nona Biosciences Partners with Kodiak Sciences to Discover Multi-Target Ophthalmic Antibodies

Fineline Cube Dec 10, 2024

Nona Biosciences, a wholly-owned subsidiary of HBM Holdings Ltd (HKG: 2142), has joined forces with...

Company Drug

Eisai’s Urece (Dotinurad) Approved by China’s NMPA for Gout Treatment with Hyperuricemia

Fineline Cube Dec 10, 2024

Eisai’s (TYO: 4523) China unit has announced that it has received marketing approval from the...

Company Drug

Daiichi Sankyo and AstraZeneca’s Datopotamab Deruxtecan Earns FDA Breakthrough Therapy Designation

Fineline Cube Dec 10, 2024

Partners Daiichi Sankyo (TYO: 4568) and AstraZeneca (AZ, NASDAQ: AZN) have jointly announced that their...

Company Deals

Shanghai Pharmaceuticals and Sichuan Kelun-Biotech Partner to Expand Sacituzumab Tirumotecan Market Access

Fineline Cube Dec 10, 2024

Shanghai Pharmaceuticals (SHA: 601607; SPH) has entered into a strategic partnership with Sichuan Kelun-Biotech Biopharmaceutical...

Company Drug

China Medical System’s Methylthioninium Tablets Receive First Prescriptions for Colonoscopy Use

Fineline Cube Dec 10, 2024

China Medical System Holdings (CMS; HKG: 0867) has announced that the first prescriptions have been...

Company Drug

Dizal Pharmaceutical Unveils Promising Data on DZD8586 for B-NHL at ASH Annual Meeting

Fineline Cube Dec 10, 2024

China-based Dizal Pharmaceutical Co., Ltd (SHA: 688192) has presented new data from a pooled safety...

Company Drug

AbbVie’s Tavapadon Shows Positive Results in Phase III TEMPO-2 Study for Parkinson’s Disease

Fineline Cube Dec 10, 2024

US-based pharmaceutical company AbbVie (NYSE: ABBV) has revealed positive top-line results from the pivotal Phase...

Company Drug

Eli Lilly’s Jaypirca Demonstrates Superiority in BRUIN CLL-321 Study for CLL/SLL Treatment

Fineline Cube Dec 10, 2024

US pharmaceutical major Eli Lilly and Company (NYSE: LLY) unveiled the latest data from the...

Policy / Regulatory

CDE Releases 89th Batch of Reference Preparations for Generic Quality Consistency

Fineline Cube Dec 10, 2024

The Center for Drug Evaluation (CDE) in China has announced the selection of the 89th...

Company Deals

Jiangsu Hengrui Pharmaceuticals Plans Secondary Listing on Hong Kong Stock Exchange

Fineline Cube Dec 10, 2024

Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276) has confirmed reports regarding its intention to make...

Company Drug

Keymed Biosciences Presents CM336 Data for Relapsed Multiple Myeloma at ASH Annual Meeting

Fineline Cube Dec 10, 2024

China-based Keymed Biosciences Inc., (HKG: 2162) has announced the presentation of the latest data from...

Company Drug

Antengene’s Xpovio Showcases Positive Results in Phase III BENCH and Phase I/II TOUCH Studies at ASH 2024

Fineline Cube Dec 10, 2024

China-based Antengene Corporation Limited (Antengene, HKG: 6996) announced the presentation of the latest results from...

Company Drug

Lee’s Pharmaceutical Receives NMPA Approval for Generic Glaucoma Treatments

Fineline Cube Dec 10, 2024

China-based Lee’s Pharmaceutical Holdings Ltd (HKG: 0950) subsidiary, Zhaoke Ophthalmology Ltd (HKG: 6622), has announced...

Policy / Regulatory

NMPA Proposes Draft for Simplified Registration of Traditional Chinese Medicines from Hong Kong and Macao

Fineline Cube Dec 10, 2024

The National Medical Products Administration (NMPA) has issued the “Notification on Simplifying the Registration and...

Policy / Regulatory

China’s NHSA and NHC Issue Guidelines to Enhance Volume-based Procurement Mechanism

Fineline Cube Dec 10, 2024

The National Healthcare Security Administration (NHSA) and National Health Commission (NHC) of China have released...

Company Drug

CSPC Pharmaceutical Group’s SYHX2011 for Metastatic Breast Cancer Accepted for NMPA Review

Fineline Cube Dec 10, 2024

China-based CSPC Pharmaceutical Group Co., Ltd. (HKG: 1093) has announced that the National Medical Products...

Company Drug

GSK’s Nucala Receives FDA Review for COPD Indication Based on MATINEE Study Data

Fineline Cube Dec 10, 2024

UK-based pharmaceutical giant GSK (NYSE: GSK) has announced that the US Food and Drug Administration...

Company Deals

Hantech Medical Device Co., Ltd Acquires BD’s Villamarzana Factory to Expand Manufacturing

Fineline Cube Dec 10, 2024

China-based Hantech Medical Device Co., Ltd, a Contract Development Manufacturing Organization (CDMO) specializing in medical...

Company Deals

Precision Biotech and T&L Biotechnology Form Partnership to Advance Cell and Gene Therapies

Fineline Cube Dec 10, 2024

China-based Precision Biotech has announced a strategic partnership with compatriot firm T&L Biotechnology Co., Ltd....

Company Medical Device

MicroPort Scientific Corp. Launches FireFalcon Balloon for Coronary Interventions with NMPA Approval

Fineline Cube Dec 10, 2024

Shanghai-based medical device giant MicroPort Scientific Corp., (HKG: 0853) has announced that it has received...

Posts pagination

1 … 249 250 251 … 666

Recent updates

  • Basecare Medical Device Secures NMPA Approval for Gems Embryo Culture Medium – Chinese IVF Specialist Completes Global Regulatory Triad
  • Pfizer’s Hympavzi Gains European Approval for Hemophilia with Inhibitors – Novel TFPI-Targeting Therapy Offers Weekly Subcutaneous Alternative to Factor Replacement
  • Henlius Biotech Secures Australian TGA Approval for HLX48 Phase I Trial – Novel EGFR/c-Met Bispecific ADC Targets Advanced Solid Tumors
  • Takeda Reports $28.5B Revenue in FY2025 Despite Vyvanse Patent Cliff – 78% Net Profit Surge Amid $1.26B Restructuring Plan
  • China’s CDE Reports Record Drug Review Activity in 2025 – Breakthrough Therapy Designations Surge 11% as Regulatory Filings Hit 20,149
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Medical Device

Basecare Medical Device Secures NMPA Approval for Gems Embryo Culture Medium – Chinese IVF Specialist Completes Global Regulatory Triad

Company Drug

Pfizer’s Hympavzi Gains European Approval for Hemophilia with Inhibitors – Novel TFPI-Targeting Therapy Offers Weekly Subcutaneous Alternative to Factor Replacement

Company Drug

Henlius Biotech Secures Australian TGA Approval for HLX48 Phase I Trial – Novel EGFR/c-Met Bispecific ADC Targets Advanced Solid Tumors

Company

Takeda Reports $28.5B Revenue in FY2025 Despite Vyvanse Patent Cliff – 78% Net Profit Surge Amid $1.26B Restructuring Plan

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.